CoChat

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2

Open access
Tung, Min-Che, Lin, Po-Lin, Wang, Yao-Chen, He, Tsung-Ying, Lee, Ming-Ching, Yeh, Sauh-Der, Chen, Chih-Yi, Lee, Huei · 2015 · Oncotarget
Cited by 138

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Min-Che Tung 1,3,* , Po-Lin Lin 4,* , Yao-Chen Wang 6 , Tsung-Ying He 4 , Ming-Ching Lee 7 , Sauh-Der Yeh 1 , Chih-Yi Chen 5 and Huei Lee 2 1 Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan 2 Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan 3 Department of Surgery, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan 4 Institute of Medicine, Department of Surgery, Chung Shan Medical University, Taichung, Taiwan 5 Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University, Taichung, Taiwan 6 Division of Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan 7 Department of Thoracic Surgery, Taichung Veteran General Hospital, Taichung, Taiwan * These authors contributed equally to this work Correspondence to: Huei Lee, email: // Keywords : Nrf2, p53, cisplatin sensitivity, lung cancer Received : July 20, 2015 Accepted : September 30, 2015 Published : October 19, 2015 Abstract Nrf2 is a key transcription factor for genes coding for antioxidants, detoxification enzymes, and multiple drug resistance and it also confers resistance to anticancer drugs. Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Luciferase reporter assays and real-time PCR analysis indicated that the Nrf2 promoter activity and its mRNA levels were markedly suppressed by wild-type p53, but not by mutant p53. Chromatin immunoprecipitation (ChIP) further confirmed that wild-type p53 binds at the p53 putative binding site to block Sp1 binding to the Nrf2 promoter and consequently to suppress the Nrf2 promoter activity. The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6150

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 138

Metadata

Authors
Tung, M.-C., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., Yeh, S.-D., Chen, C.-Y., & Lee, H.
Venue
Oncotarget
Published
2015-10-19
Volume
6
Issue
39
Pages
41692-41705
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1859299832
Cited by
138
References
11
FWCI
4.37
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. https://app.cochat.ai/papers/10.18632/oncotarget.6150
The paper
Tung, M.-C., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., Yeh, S.-D., Chen, C.-Y., & Lee, H. (2015). Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Oncotarget. https://doi.org/10.18632/oncotarget.6150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.